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Putative cancer stem cells have been identiﬁed in glio-
blastomas and are associated with radio- and chemo-
resistance. Further knowledge about these cells is thus
highly warranted for the development of better glioblas-
toma therapies.
Gene expression analyses of 11 high-grade glioma cul-
tures identiﬁed 2 subsets, designated type A and type B
cultures. The type A cultures displayed high expression
of CXCR4, SOX2, EAAT1, and GFAP and low
expression of CNP, PDGFRB, CXCL12, and extracellu-
lar matrix proteins. Clinical signiﬁcance of the 2 types
was indicated by the expression of type A– and type
B–deﬁning genes in different clinical glioblastoma
samples. Classiﬁcation of glioblastomas with type A–
and type B–deﬁning genes generated 2 groups of
tumors composed predominantly of the classical,
neural, and/or proneural subsets and the mesenchymal
subset, respectively. Furthermore, tumors with EGFR
mutations were enriched in the group of type A
samples. Type A cultures possessed a higher capacity
to form xenograft tumors and neurospheres and dis-
played low or no sensitivity to monotreatment with
PDGF- and IGF-1–receptor inhibitors but were efﬁ-
ciently growth inhibited by combination treatment
with low doses of these 2 inhibitors. Furthermore,
siRNA-induced downregulation of SOX2 reduced
sphere formation of type A cultures, decreased
expression of type A–deﬁning genes, and conferred sen-
sitivity to monotreatment with PDGF- and IGF-1–
receptor inhibitors.
The present study thus describes a tumor- and neuro-
sphere-forming SOX2-dependent subset of glioblastoma
cultures characterized by a gene expression signature
similartothatoftherecentlydescribedclassical,proneural,
and/or neural subsets of glioblastoma. The ﬁndings that
resistance to PDGF- and IGF-1–receptor inhibitors is
r e l a t e dt oS O X 2e x p r e s s i o na n dc a nb eo v e r c o m eb yc o m -
binationtreatmentshouldbeconsideredinongoingefforts
to develop novel stem cell–targeting therapies.
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A
ccording to the cancer stem cell hypothesis, the
bulk of tumor cells are derived from a smaller
subset of cells that have a series of stem-like phe-
notypic traits, including self-renewal, skewed cell div-
ision, and potential for multilineage differentiation.
1,2
During past years, tentative cancer stem cells have
been isolated from many types of solid tumors.
3–8
However, the molecular characteristics of cancer stem
cells are still poorly deﬁned, and it also remains
unclear from which cells they originate.
In the case of brain tumors, multiple studies have
reported the isolation of brain cancer stem cells from
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3,4 The tentative
glioma stem cells display high capacity for self-renewal,
limited differentiation, and a disturbed karyotype and
were mainly isolated because of their expression of
CD133. It was reported that CD133
+ cells implanted
intomousebraincanrecapitulatethehistologyoftheorig-
inal tumor, implying that the original tumors were indeed
derived from these cells.
3,4,9,10 Investigation of CD133
expression in paired, newly diagnosed, and recurrent
gliomas also revealed an increase in the CD133
+ popu-
lation in recurrent tumors, suggesting a role for these
cells in tumor progression after treatment. However,
both CD133
+ and CD133
- glioma stem cells were later
described, and CD133
- brain tumor cells also formed
tumors in orthotopic transplantation experiments.
11–13
Tumorigenic clones of CD133
+ and CD133
- cancer cells
coexist in the same tumor, and capacities for self-renewal
and tumor initiation need not be restricted to a uniform,
infrequentsubpopulationofcells.
11,14Aparticulardepen-
denceofbraintumorstemcellsonhostfactorsprovidedby
thespecialmicroenvironmentoftheperivascularspacehas
also been suggested.
15
With use of lineage-speciﬁc conditional knockout of
tumor-suppressor genes in mouse brain, it was recently
shown that highly malignant astrocytic brain tumors
can originate from the neural stem cells residing in the
subventricular zone of the lateral ventricle wall and in
the subgranular zone of the dentate gyrus.
16–18 Of
importance, tumor suppressor gene knockout (p53/
Pten/Nf1) was associated with an increased capacity of
cellstogrowasneurospheres,supportingthesigniﬁcance
ofthisinvitrophenotypeasafeatureofcancerstemcells.
Brain tumor stem cells have been compared with
regard to growth factor dependency and sensitivity to
irradiation.
19 Other data have suggested unique
responses of cancer stem cells to manipulations of
certain signaling pathways, including the bone morpho-
genetic protein (BMP),BMI1polycomb ring ﬁngeronco-
gene, and hedgehog-GLI pathways; L1 cell adhesion
molecule; cMYC; peroxisome proliferator-activated
receptor gamma; and Notch.
20–27 Autocrine transform-
inggrowthfactorbetasignalingwasreportedtomaintain
stemness of glioma-initiating cells via sex determining
region Y-box 4 (SOX4) and sex determining region Y-
box 2 (SOX2).
28
In previous studies, we characterized a panel of glio-
blastomacultures with regardtotheirsensitivityto imati-
nib and NVP-AEW541. These low-molecular-weight
tyrosine kinase inhibitors were selected on the basis of
theirabilitytotargetplatelet-derivedgrowthfactorrecep-
tors (PDGFRs) and insulin-like growth factor–1 receptor
(IGF-1R) signaling, respectively. The target proﬁle and
speciﬁcities of thesecompoundshave been described else-
whereindetail.
29,30PDGFRsignalinghasbeenimpliedin
glioblastomabiologythroughstudiesbasedonanalysesof
humantumortissue,ofculturedglioblastomacells,andof
mouse glioblastoma models.
31–35 Furthermore, imatinib
and hydroxyurea have demonstrated promising activity
in phase II studies on recurrent glioblastoma.
36,37 More
recently, a negative phase III study with the same combi-
nation was reported in an unselected group of patients
with recurrent glioblastoma,
38 suggesting the need for
combination therapies and improved patient selection.
IGF1-R signaling has been described in glioblastoma,
and ﬁndings from various preclinical studies suggest
favorable combination effects when IGF1-R inhibitors
have been combined with other receptor tyrosine kinase
(RTK)-targeting agents.
39–43
In the present study, we further characterized a set of
11 high-grade glioma cultures. This effort has led to the
identiﬁcation of a SOX2-dependent subset of neuro-
sphere- and tumor-forming glioma cells with distinct
sensitivity to a combination of tyrosine kinase inhibitors
targeting PDGFRs and IGF-1R.
Results
Identiﬁcation of 2 Gene Expression–Based Subsets of
High Grade Glioma Cultures
Previouslypublishedgeneexpressiondatafromapanelof
glioblastomacultureswerecombinedwithpublished
44,45
and novel data on the sensitivity of these cells to imatinib
and the IGF-1R inhibitor NVP-AEW541 (Supplemental
Fig. 1). As shown in Fig. 1A, these analyses revealed an
association between one of the gene expression–based
clusters and low sensitivity to monotreatment with
either imatinib or NVP-AEW541.
This group of low-sensitivity cultures (cultures 21,
18, 35, and 38) also formed a cluster in a second hier-
archical clustering analysis, based on the expression of
285 differentially expressed genes, in an analysis per-
formed on the 11 cultures that were still available for
experimental studies (Fig. 1B). Cluster robustness analy-
sis revealed high robustness with R- and D-index values
of 1 and 0, respectively.
46 The same 2 groups were
formed when clustering was performed on the basis of
the expression of 553 or 1339 features ﬁltered by less
stringent criteria (data not shown).
For continued analyses, the low-sensitivity group
of cells was tentatively designated type A cultures,
whereas the other group of cells was referred to as type
B cultures (Fig. 1B).
Type A Cultures are GFAP Positive, Whereas Type B
Cultures Display Mesenchymal Features
A signiﬁcance analysis of microarrays (SAM) analysis
was performed to investigate differences in gene
expression between the type A and type B cultures and
identiﬁed 34 genes with .3-fold difference in expression
between the 2 groups (Supplemental Table 1A). The
dominating categories were genes encoding secreted
soluble proteins, extracellular matrix proteins, and tran-
scription factors.
The most striking observation was that all 6 differen-
tially expressed genes that code for extracellular matrix
proteins showed higher expression in type B cultures
(see Supplemental Table 1A for details). Among the
genes encoding secreted soluble proteins, 4 were highly
expressed in type A cultures (Norris disease
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NEURO-ONCOLOGY † NOVEMBER 2011 1179Fig. 1. Identiﬁcation of 2 subsets of high-grade glioma cultures, type A and type B, based on gene expression. (A) Unsupervised hierarchical
clustering of 20 high-grade glioma cultures, their growth rate as doublings per 4 days, and imatinib and NVP-AEW541 sensitivity. Response of
.40% growth inhibition to drug treatment is indicated with +, ,20% is indicated as –, and 20%–40% is indicated with *. 1 mMi m a t i n i bo r
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14 [CXCL14], CD70, tumor necrosis factor ligand super
family member 7 [TNFSF7], and pleiotrophin [PTN]),
whereas 5 gene products were more abundant in type
B cultures (gremlin 1 [CKTSF1B1], insulin-like growth
factor binding protein 3 [IGFBP3], insulin-like growth
factor binding protein 7 [IGFBP7], stroma-derived
factor 1 [SDF1 or CXCL12], and wingless-type
MMTV integration site family member 5A [WNT5A]).
Among genes encoding transcriptional regulators only,
SRY-box 9 (SOX9) was more highly expressed in type
A, whereas 5 transcriptional regulators (Kruppel-like
factor 4 [KLF4], necdin homolog [NDN], forkhead
box F2 [FOXF2], pleiomorphic adenoma gene-like
1 [PLAGL1], nuclear receptor subfamily 2 group F
member 1 [NR2F1]) were highly expressed in type B cul-
tures. Another striking observation was that expression
of glial ﬁbrillary acidic protein (GFAP) was a unique
feature of type A cultures.
In summary, type B cultures showed high expression
of genes encoding extracellular matrix proteins,
suggesting mesenchymal features of this subset. This
description was also supported by their high expression
of regulator of G protein signaling 5 (RGS5), which has
been described as a marker for brain pericytes and peri-
vascular smooth muscle cells.
47 Type A cultures, in con-
trast, were characterized by high expression of GFAP. Of
interest, GFAP expression is also a feature of normal
subventricular zone neuroepithelial stem cells in mice
48
and of early progenitors.
49
Gene Set Enrichment Analysis Identiﬁes Candidate
Mechanisms Regulating Type A and Type B Expression
Characteristics
Gene set enrichment analysis (GSEA) was used to
analyze differences in transcription factor proﬁles
between type A and type B cultures. The top 5 transcrip-
tion factor sets were Friend leukemia virus integration 1
(FLI1), SMAD family member 1 (SMAD1), jun B proto-
oncogene (JUNB), nuclear factor I/C (NFIC), and Spi-C
transcription factor (SPIC), and their target genes were
highly expressed in type B cells. OCT4 (POU5F1) was
the seventh signiﬁcant transcription factor gene set,
and these target genes were higher expressed in type A
cells (data not shown). A microRNA gene set analysis
was also performed. Genes in the mir-486, mir-203,
and mir-703 regulated gene sets were highly expressed
in type B cells, mir-467 and mir-519 regulated gene
sets showed higher expression in type A cells.
In summary, GSEA suggests that genes characterizing
type A and type B cells are regulated by different mech-
anisms, potentially involving transcription factors and
microRNAs.
Type A and Type B Cultures Vary with Regard to
Expression of Lineage Markers
The differential expression of developmental regulatory
genes, such as CKTSF1B1 (BMP-inhibitor gremlin 1),
the frizzled ligand NDP (Norrin), WNT5A, SOX9,
and KLF4 and of GFAP indicated that the 2 types of
glioma cultures possibly represent derivatives of differ-
ent developmental lineages. Because only a few
markers of adult neuroepithelial stem cells and their dif-
ferentiated progeny were available in the microarray
data set, we performed quantitative polymerase chain
reaction (qPCR) analysesto test a set of 17 genes, includ-
ing genes previously implicated as markers for neuro-
epithelial stem cells and different derivatives of these
cells (Supplemental Table 2). Hierarchical clustering
based on qPCR data of these genes yielded a subdivision
composed of 2 sets of cultures identical with the 2 sets
produced by the array data (Supplemental Fig. 2).
Eight of the 17 genes showed an expression pattern
that clearly differed between the type A and type B cul-
tures (Fig. 1C, Supplemental Table 3). Chemokine C-X-
C receptor 4 (CXCR4), SOX2, excitatory amino acid
transporter 1 (EAAT1), and GFAP were more highly
expressed in type A cultures, whereas 2′,3′-cyclic nucleo-
tide 3′ phosphodiesterase (CNP), PDGFRB, laminin
gamma 1 (LAMC1), and CXCL12 were more highly
expressed in type B cultures. Two suggested neuroe-
pithelial stem cell markers, NESTIN and BMI1, did
not show any clear difference between type A and type
B cultures (Fig. 1C, Supplemental Table 3) and neither
did CD133 (data not shown). In contrast, SOX2 was
highly expressed in type A cultures. Finally, type B cul-
tures showed higher expression of genes associated
with microglial and perivascular cells (LAMC1 and
PDGFRB) and a gene associated with the oligodendro-
cyte lineage (CNP).
Type A and Type B Proﬁles Identify Molecular Subsets
of Glioblastoma
To investigate the clinical signiﬁcance of the 2 gene
expression–deﬁned subsets of cultures, the expression
proﬁles of the type-deﬁning genes were analyzed in
human glioblastoma samples. For this purpose, 8
3 mMNVP-AEW541wasusedintheseexperiments.(B)Hierarchicalclusteringofasubsetof11cellculturesdividestheculturesinto2distinctgroups
deﬁned as type A cultures (21, 18, 35, and 38) and type B cultures (31, 34, 45, 11, 8, 7, and 4). (C) Expression levels, as determined by qPCR, of
8s t e m /progenitor cell and differentiation markers that display differential expression between type A and type B cultures are shown in the left
and right graphs. The middle graph shows the relative expression of 4 genes that did not differ clearly between type A and type B cultures.
Shortened bars have their relative expression level stated above them. (D) Supervised analysis of expression data from TCGA glioma samples by
type A– and type B–deﬁning genes distinctly divides the samples to match previous data in which the type A group consists of classical,
proneural, and/or neural tumors and is enriched with EGFR-mutated samples, and type B consists of gliomas with mesenchymal features (Fisher’s
exacttest,EGFR-mutated,P ¼ .02;mesenchymalsubset,P ,.001).Colorcodeforexpressionisredforhighexpressionandblueforlowexpression.
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by qPCR (Fig. 1C) and the top 4 upregulated or down-
regulated genes identiﬁed in the SAM analysis
(Supplemental Table 1A) were used to analyze 3 publicly
available gene expression data sets.
50–52 Twoof the data
sets were analyzed by hierarchical clustering to visualize
the expression pattern of the type-deﬁning genes in
glioma tissue. Data from the Cancer Genome Atlas
(TCGA) were analyzed in a supervised fashion to ident-
ify novel correlations to genetic events and gene
expression–based subsets of human glioblastomas.
52
Hierarchical clustering analysis of a set of 14 high-
grade gliomas demonstrated coexpression of type A
genes and type B genes.
51 In this data set, expression
datacouldonlyberetrievedfor13ofthe16type-deﬁning
genes. Type A and type B genes were completely segre-
gated between 2 cluster arms, with the exception of
CXCR4 and RGS5 (Supplemental Fig. 3A). The same
analysis of a larger set of human glioblastoma-derived
gene expression data that consisted of 49 glioma
samples generated 3 cluster groups of coexpressed genes
(Supplemental Fig. 3B). The ﬁrst branch was composed
of only type B genes, and the other 2 contained only
type A genes. The tumor samples appeared to be nonran-
domly distributed in the 3 different cluster branches with
respect to the described proliferative, mesenchymal, and
proneural tumor subsets. Branch 1 contained 10
samples of the proliferative and 14 samples of the
mesenchymal subset; branch 2 contained 6 proliferative,
5 proneural, and 3 mesenchymal samples; and branch 3
contained 8 samples of the proliferative and 3 samples
ofthemesenchymalsubset.Statisticalanalysesconﬁrmed
signiﬁcant associations between the cluster branches and
the molecular glioblastoma subsets.
50
Because the type-deﬁning genes cocluster in tissue
samples, they were used for a supervised analysis of
expression data from the TCGA data set of glioma
samples.
52 In this analysis of 138 samples, 39 were deter-
mined to be of type A character, 26 of type B, and 73 of
neither. These A and B sets of tumor samples were then
compared with regard to mutated or ampliﬁed genes and
distribution of the 4 gene expression–based glioblastoma
subsets: classical, neural, proneural, and mesenchy-
mal.
53–55 The type A group was found to be enriched
with samples carrying mutated and/or ampliﬁed epider-
mal growth factor receptor (EGFR)( F i g .1D and not
shown) and the samples were a mixture of the classical,
neural, and/or proneural subsets, whereas the type B
groupwasstronglyenrichedwithsamplesofthemesench-
ymal subset (Fig. 1D). Neither the type A nor the type B
subset showed any signiﬁcant enrichment of tumors with
isocitrate dehydrogenase 1 (IDH1) mutations or the
methylator phenotype; however, 2 of 3 samples with
SOX2 gene ampliﬁcation were in the type A group, and
the third was among the nonseparated tumor samples.
Together, these results demonstrate that the selected
type A– and type B–deﬁning genes are expressed in
different sets of human tumors rather than coexpressed
in the same tumors. The analyses also demonstrate
that the type A– and type B–deﬁning genes, when
used in unsupervised clustering analyses or as classiﬁer
genes, divide tumor sets into different clusters that
display a nonrandom content of previously described
molecular glioblastoma subsets.
50,53
Immunoﬂuorescence Staining Demonstrates Expression
of GFAP and SOX2 in Type A Cells
The qPCR analyses suggested that high GFAPand SOX2
expression were features of type A cultures (Fig. 1C). To
further explore this ﬁnding, immunoﬂuorescence stain-
ing of GFAP and SOX2 was performed on 2 type A
and 2 type B cultures.
GFAP
+ cells were found only in type A cultures. It
was also noted that GFAP was restricted to 10%–80%
of cells in early passages and to 1%–5% of cells in
later passages (data not shown). By immunoﬂuorescence
staining, it was observed that nuclear SOX2 protein was
present in both GFAP
+ and GFAP
- cells of type A cul-
tures (Fig. 2). SOX2 was not detected in type B cultures
(Fig. 2).
This experiment thus conﬁrmed that type A and type
B cultures differ with regard to GFAP and SOX2
expression. The restricted expression of GFAP to a
subset of cells is compatible with these cells dividing
asymmetrically to generate progeny that retain or lose
GFAP expression. However, the presence of SOX2 in
most cells of the type A cultures indicates a tissue stem
and/or progenitor cell phenotype of a majority of
these cells.
Type A Cultures Display Increased Ability to Form
Tumors in vivo and Neurospheres in vitro
Pieces of the original tumor tissue were used for in vivo
subcutaneous tumor growth in severe combined immune
deﬁciency (SCID) mice. All 8 tissue preparations of
tumors from which type A cultures were derived
formed tumors in vivo (Fig. 3A). In contrast, tumor for-
mation was only observed with 4 of the 12 tissue prep-
arations of tumors representing the type B cultures
(Fig. 3A).
Furthermore, cultures18 and 38 (type A) and cultures
7 and 8 (type B) were used for subcutaneous xenograft
assays in SCID mice. Both type A cultures resulted in
tumors, but not the type B cultures (Fig. 3A).
As an additional method to examine cancer stem cell
properties of the cultures, neurosphere assays were per-
formed. Type A and type B cultures displayed different
abilities to form spheres (Fig. 3B and C). Type A cultures
generally formed a higher number of spheres, and these
were also larger than the spheres formed by type B cul-
tures (Fig. 3B). Similar results were observed when ana-
lyzing the ability to form serial spheres (datanot shown).
To further address the self-renewal capacity of the
glioma cultures, limiting dilution assays were applied to
2 cultures of type A and 1 culture of type B. The fraction
of sphere-forming cells was calculated to be 1.2% and
0.8% in cultures 18 and 38, respectively (Fig. 3C). In
this assay format, the fraction of sphere-forming cells in
the type B culture 8 was below the detection level
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with regard to tumor- and sphere-forming capacities,
which are more pronounced in the type A cultures.
The Sphere-forming Phenotype of Type A Cultures is
SOX2 Dependent
One of the molecular features that most clearly discrimi-
nated between type A and type B cultures was the
expression of SOX2, which is known as a progenitor
cell transcription factor capable of contributing stem
cell characteristics to somatic cells.
56,57 We therefore
tested whether the cancer stem cell features of type A
cultures were dependent on SOX2.
The differential expression of SOX2 between type A
and type B cultures was conﬁrmed by immunoblotting
(Fig. 4A and data not shown). siRNA-mediated SOX2
downregulation in cultures 18 and 21, using a pool of
4 siRNAs, resulted in a decreased growth rate of the cul-
tures, which was most evident for culture 18 (Fig. 4A
and B). Moreover, the expression of type A–deﬁning
genes (CXCR4, EAAT1, and GFAP) was decreased in
both cultures (Fig. 4C). Of importance, SOX2 siRNA–
treated cells also displayed signiﬁcantly reduced neuro-
sphere formation capacity, with fewer and smaller
spheres, compared with control siRNA-treated cells
(Fig. 4D). Similar results were obtained with an indepen-
dent SOX2 siRNA from another provider (Supplemental
Fig. 5).
From these data, we conclude that the neurosphere-
forming ability and the deﬁning gene expression signa-
ture of type A cultures are dependent on SOX2.
Type A Cultures are Highly Susceptible to Combination
Treatment with Imatinib and NVP-AEW541
One possible explanation for the reduced sensitivity of
type A cultures to monotreatment with the 2 tyrosine-
kinase inhibitors (Fig. 1A) could be a higher extent of
redundancy in growth factorsignaling intype A cultures.
It was therefore analyzed whether the growth-inhibitory
response could be enhanced by combination treatment
with the 2 drugs. For these analyses, 3 of the type A cul-
tures—18, 21, and 38—were selected.
Fig. 2. Immunoﬂuorescence staining demonstrates that the presence of GFAP
+ and SOX2
+ cells is restricted to type A cultures.
Immunoﬂuorescence staining of GFAP and SOX2 was performed on type A cultures 18 and 38 and type B cultures 7 and 8. Presence of
GFAP and SOX2 was restricted to type A cultures 18 and 38. Double immunoﬂuorescence analysis of SOX2 and GFAP in cells of
cultures 18 and 38 demonstrated that SOX2 is present in a majority of the cells, whereas GFAP expression varies. GFAP staining is
colored green, SOX2 red, and nuclear DAPI blue. Scale bar is 50 mm.
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showed no or low response to treatment with 0.25 mM
of imatinib or 0.1 mM of NVP-AEW541 (Fig. 5A). Of
interest, all 3 cultures displayed a signiﬁcant growth
inhibition when treated with a combination of
0.25 mM of imatinib and 0.1 mM of NVP-AEW541
(Fig. 5A). Ability of the drugs to block PDGF and
IGF-1 receptors at these concentrations was conﬁrmed
in an independent experiment monitoring receptor phos-
phorylation after combination treatment with 0.25 mM
of imatinib and 0.1 mM of NVP-AEW541 (Fig. 5B).
No evidence for synergistic effects of the 2 drugs was
detected when the combination treatment was applied
to 2 different type B cultures (data not shown).
Together, these results demonstrated that type A cul-
tures display a strong sensitivity to combination treat-
ment with low doses of imatinib and NVP-AEW541.
SOX2 Downregulation Increases the Sensitivity of Type
A Cultures to Imatinib and NVP-AEW541
To investigate whether SOX2 had any inﬂuence on sen-
sitivity to monotreatment with either of the 2 drugs in
the low-sensitivity type A cultures, SOX2 down-
regulation experiments were performed. Forthese exper-
iments, type A cell culture 18 was excluded because of
the signiﬁcant growth inhibition observed after SOX2
downregulation (Fig. 4B). SOX2 downregulation in cul-
tures 21 and 38 was conﬁrmed by SOX2 immunoblot-
ting (Supplemental Fig. 4).
In agreement with previous analyses, the control cells
displayed lackof signiﬁcant growth reduction aftertreat-
ment with 1 mM of imatinib or NVP-AEW541 (Fig. 5C).
Of interest, the SOX2 downregulation conferred a sig-
niﬁcant imatinib and NVP-AEW541 sensitivity to both
cultures (Fig. 5C).
Together, these ﬁndings identify a previously unrec-
ognized impact of SOX2 on sensitivity to PDGFR and
IGF-1R targeting. The mechanism behind this is not
known. On the basis of preliminary ﬁndings, we
cannot exclude an effect on tyrosine kinase receptor
levels and/or activities. qPCR analyses of PDGFRs and
IGF-1R after SOX2 siRNA treatment showed that
IGF-1R mRNA levels were signiﬁcantly downregulated
in cultures 18 and 21 but only marginally affected in
culture 38 (data not shown). Effects on PDGFR
mRNA levels were less distinct.
Discussion
The present study deﬁnes 2 novel phenotypically distinct
subsets of high-grade glioma cell cultures. Both types of
cultures have certain characteristics of neural stem cells,
because they both express the established stem cell–
related proteins NESTIN and BMI1. The characteristics
describing the 2 subsets are summarized in Table 1. The
features deﬁning type A cultures include higher
expression of GFAP, SOX2, SOX9, EAAT1, and
CXCR4; tumorigenic potential in vivo; a prominent
Fig. 3. Type A cultures show higher tumorigenic potential and
higher ability to form spheres and to self-renew. (A) Tumor
formation in SCID mice after subcutaneous injection of original
minced tumor tissues and of glioma cultures, representing type A
and type B subsets. Results are given as number of mice with
visible tumor per number of injected mice. (B) The ability to form
tumor spheres after 8 days of growth in neurosphere medium
was tested for type A cultures 18, 21, and 38 and type B cultures
7, 8, and 31. Type A cultures, but not type B cultures, formed a
high number of tumor spheres. Scale bar is 100 mm. (C) Limiting
dilution assays after plating of cells at limiting dilution in 200 mL
media showed a measurable fraction of sphere-forming cells in
type A cultures 18 and 38, but not in the type B culture 8.
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sensitivity to tyrosine kinase inhibitors targeting
PDGF- or IGF-1–receptors. Moreover, siRNA treat-
ment showed that the phenotype of type A cultures is
dependent on SOX2. Type B cultures are characterized
by high expression of genes encoding extracellular
matrix proteins and the mesenchymal marker RGS5
and genes associated with microglia (PDGFRB and
LAMC1) and oligodendrocytes (CNP). Clinical signiﬁ-
cance of these 2 types of cultures is indicated by the ﬁnd-
ings that type A genes and type B genes display
coordinated expression and are present in different
tumor samples when analyzed in 2 independent sets of
human glioblastoma tumors; furthermore, when used
as classiﬁer genes, they divide a set of tumors into
groups enriched in samples of different molecular
subtypes.
The overall proﬁles of type A and type B cultures,
with high expression of genes coding for mesenchymal
proteins as one characteristic of type B cultures, is
indicative of relationships to recently described subsets,
including the classical, neural, proneural, and mesench-
ymal glioblastoma subsets identiﬁed on the basis of gene
expression analyses of clinical samples in the TCGA
Fig. 4. siRNA-mediated downregulation of SOX2 in type A cultures. (A) Immunoblotting analyses of SOX2 in cells transfected with control
or SOX2 siRNA. (B) Type A cultures 18 and 21 have lower growth rate after siRNA-mediated downregulation of SOX2. Cell density was
determined after 72 h. Results are derived from 2 experiments with 10 replicates per condition. Error bars indicate standard deviation.
(C) siRNA-mediated SOX2 downregulation in type A cultures 18 and 21 leads to lower expression levels of type A genes measured by
qPCR. (D) SOX2 siRNA treatment reduces tumor sphere formation. The effect is illustrated by phase contrast microscopy (10 x
magniﬁcation) and was quantiﬁed by counting the number of spheres ≥50 mm/well. All neurosphere formation assays were repeated
4 times. The mean number of spheres in SOX2 siRNA–treated culture 18 was 102, compared with 243 in control siRNA-treated cultures
(P ≤.05). Corresponding numbers for culture 21 were 89 and 150 (P ≤.05). Scale bar is 200 mm.
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50,53,58 A supervised analysis of the TCGA data
set, based on the type-deﬁning genes, separated the
tumor samples into a mixed group of the classical,
neural, and/or proneural subsets and another group
of the mesenchymal subset. The type A tumor group
was also enriched in EGFR gene–mutated and/or–
ampliﬁed samples. High SOX2 expression is known to
characterize the proneural subset, and in the supervised
analysis of TCGA samples, we found 2 of 3
SOX2-ampliﬁed tumor samples among the type A
tumors and the third among the unseparated samples.
In an initial unsupervised hierarchical clustering analysis
using the TCGA data set, the type A genes were split into
2 cluster branches, whereas the type B genes were kept
together in 1 branch. The type A cluster contained all
8 IDH1 gene-mutated and the methylator samples,
known to also be included in the proneural subset (not
shown). There was, however, a selection against these
IDH1-mutant and/or methylator samples in the
supervised analysis because neither the A nor the B
type group contained any of these samples, although
they contained other samples of the proneural subset
(Fig. 1D). Thus, large fractions of the classical, pro-
neural, and/or neural glioblastoma subsets, including
samples with SOX2 or EGFR gene ampliﬁcations, but
not the IDH1 gene-mutated and/or methylator
samples, were identiﬁed by this classiﬁer.
Several of the suggested microRNAs and transcrip-
tion factor gene sets distinguishing type A and type B cul-
tures (Supplemental Table 1B) have been implicated in
glioma biology. Mir-425, mir-451, and mir-486 have
been reported to be highly expressed in glioma cells.
Introduction of these into glioma cells inhibited neuro-
sphere formation. Of interest, mir-451 was shown to
have a cooperative effect with imatinib.
59 OCT4
(POU5F1) is here shown to be associated with type A
cultures, similar to some of its target genes, and is
known to affect colony formation capacity and
Fig. 5. Type A cultures are growth inhibited by combination treatment with imatinib and NVP-AEW541 and display sensitivity to
monotreatment after SOX2 downregulation. (A) Type A cultures 18, 21, and 38 were untreated (control) or treated with 0.25 mM
imatinib, 0.1 mM NVP-AEW541, or the combination of 2 drugs at the same concentrations. Drug sensitivity is expressed as cell density
(percentage of untreated control). All 3 cultures demonstrated strong growth-inhibitory response after combination treatment. Asterisks
(*) represent P , .001, and “n.s.” represents nonsigniﬁcant P values. Effects on cell growth were determined after 4 days of drug
exposure. Media and drug was changed after 2 days of culture. The data shown are derived from 3 independent experiments: 1
performed with duplicate and 2 with quadruplicate measurements. (B) Immunoblotting analyses of PDGFR and IGF-1R tyrosine
phosphorylation after monotreatment with 1 mM imatinib or NVP-AEW541 or combination treatment with 0.25 mM imatinib and
0.1 mM NVP-AEW541. A total of 100 ng/mL PDGF-BB or 50 ng/mL IGF-1 was used to stimulate the cells for 10 min at 378C. (C) Cell
cultures 21 and 38 were transfected with either SOX2 siRNA or control siRNA. Drug treatment with either 1 mM imatinib or 1 mM
NVP-AEW541 was started 24 h after transfection and was maintained for 72 h. Cultures with SOX2 downregulation demonstrated
signiﬁcant growth reduction after treatment with either drug. Results are derived from 2 experiments. Error bars indicate standard
deviation. Asterisks (*) represent P ≤.01, and “n.s.” represents nonsigniﬁcant.
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60 In addition, OCT4 has
the potential to reprogram ﬁbroblasts into pluripotent
stem cells in combination with SOX2, Kruppel-like
factor 4 (KLF4), and c-MYC.
56 These data suggest
highly relevant mechanisms that also could be involved
in generating the differences in phenotypes observed
between type A and type B cultures.
Among the 11 cultures of the present study, 4 type A
cultures and 6 type B cultures have previously been
characterized with regard to phosphatase and tensin
homolog (PTEN) protein expression, phosphoinositide-
3-kinase (PI3K) mutations, and serum sensitivity of
serine/threonine protein kinase Akt (Akt) phosphoryl-
ation.
44 Aberrations of this pathway were found in
both type A and type B cultures, suggesting heterogen-
eity with regard to mutational activation of growth
factor pathways in the 2 subsets.
The contrasting characteristics between type A and
type B cultures and/or tumors are relevant in the
context of other recent studies on brain cancer stem
cells. The GFAP expression and SOX2 dependency of
type A cultures suggest a relationship to the cancer-
forming cells identiﬁed in studies in which brain
tumors were induced in mice by inactivation of tumor
suppressors in neural stem cells.
16–18 On the other
hand, the expression of PDGFRB and RGS5 in type B
cultures suggests similarities to the CD133
+/NESTIN
+
glioblastoma cells that were identiﬁed in perivascular
niches.
15 Furthermore, EGFR expression deﬁned a set
of glioblastoma tumor–initiating cells.
61 Because
several types of tentative glioblastoma stem cells have
been described in the literature, a potential topic for
future studies will be to explore the possibility that
type A and type B cells coexist in tumors and constitute
cell types with complementary functions. This type of
tumor-promoting intratumoral heterogeneity of malig-
nant cells is attracting increasing interest, and exper-
imental support for this notion was recently provided
in a study on glioma
62 and in a genetic model of small
cell lung cancer.
63 However, the fact that the type A–
and type B–deﬁning gene sets also deﬁne distinct
subsets of tumors in vivo favors the idea that the 2 stem-
like cancer cell populations described here are present in
and determine the phenotype of different sets of tumors
rather than occur mixed in the same tumor.
Furthermore, in a recent analysis of human glioma
samples, we found that SOX2, together with pluripo-
tency factors OCT4 and Nanog, was quite homoge-
nously expressed in glioblastoma tumors.
64
Studies of cancer stem cells are spurred by expec-
tations to improve therapy. In this context, it is note-
worthy that the type A cultures identiﬁed in this
study displayed a consistent high sensitivity to combi-
nation treatment with inhibitors of PDGF and IGF-1
receptors, whereas monotreatment was not efﬁcient.
Coactivation of multiple tyrosine kinases is a well-
known phenomenon in glioma.
65,66 Clinical trials
with imatinib for high-grade gliomas have, in
general, not yielded major positive results.
36,67,68 The
present work should prompt studies on whether the
small fraction of responsive tumors have characteristics
of type A or type B cultures. The ﬁnding that resistance
among type A cultures to PDGF- and IGF-I–receptor
inhibitors can be overcome by combination treatment
suggests that this combination is highly interesting for
ongoing efforts to develop novel stem cell–targeting
therapies. Of note, type A cultures displayed high
expression of the chemokine receptor CXCR4.
Inhibitors of CXCR4 have already demonstrated
growth inhibitory effects in various glioma model
systems
69 and have effects on proliferation of glioblas-
toma progenitor cells.
70 The ﬁnding that the type A
phenotype depends on high levels of SOX2 suggests
that SOX2 is a potential target for treatment. Such
initiatives are also spurred by the very recent identiﬁ-
cation of SOX2 as an important oncogene in lung
and esophageal squamous cell carcinoma.
71 SOX2 is
universally expressed in neuroglial tumors
72 and
together with other pluripotency genes in glioblas-
toma.
64 It was indicated that silencing of SOX2 in glio-
blastoma may affect proliferation and tumorigenicity.
73
Material and Methods
Establishment of Cell Cultures and Analysis of
Sensitivity to Receptor Tyrosine Kinase Inhibitors
The establishment of the 20 high-grade glioma cultures
used here and analyses of their sensitivity to imatinib
and NVP-AEW541 has been described elsewhere.
44,45
Immunoblotting analyses to monitor effects of drugs
Table 1 Characteristics deﬁning type A and type B high grade
glioma cultures
Variable Type A
cultures
Type B
cultures
expression of neural stem cell markers,
NESTIN and BMI1
high high
expression of GFAP, SOX2 and SOX9 high low
expression of mesenchymal markers low high
tumorigenic potential high low
neurosphere growth and self-renewal
capacity
high low
SOX2-dependent stem cell phenotype yes n.a.
sensitivity to mono-treatment with
imatinib gene, or NVP-AEW541
low high
sensitivity to combination-treatment
with imatinib and NVP-AEW541
high n.a.
SOX2-dependent resistance to
mono-treatment with imatinib or
NVP-AEW541
yes n.a.
TCGA related tumors with EGFR gene
ampliﬁcation and/or mutation
yes no
TCGA related tumors with classical/
pro-neural/neural gene expression
signature
yes no
TCGA related tumors with
mesenchymal gene expression
signature
no yes
n. a., not applicable.
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described elsewhere.
44,45
Generation of Gene Expression Data
Experiments followed standard and published pro-
cedures (see Supplemental Material). qPCR analyses
were performed on cDNA isolated from the glioblas-
toma cultures and analyzed with an ABI Prism 7500
(Applied Biosystems). Expression levels were normalized
to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) expression. Microarray analyses relied on
previously published gene expression data,
45 which has
been deposited at EMBL-EBI Array Express with acces-
sion number E-MEXP-1063. The passage number of the
glioma cell cultures used for the gene expression analysis
ranged from 5 to 10. Cluster analysis of glioblastoma
tumor samples used publicly available datasets
50,51
(data is accessible at http://www-genome.wi.mit.edu/
cancer/pub/glioma and through GEO at accession
number GDS1816 and at the TCGA data portal).
Immunoﬂuorescence Staining
Primary antibodies used were mouse monoclonal
anti-GFAP (Sigma) and rabbit anti-SOX2 polyclonal
antibody (Chemicon ab5603). Bound antibodies were
visualized by ﬂuorophore-conjugated secondary anti-
bodies (Dako, GE Healthcare, Abcam). Cells were ana-
lyzed using a Zeiss Axioplan 2 microscope, and images
were collected with AxioCam HRm Camera and
Axiovision software, version 4.2 (further details in
Supplemental Material).
Glioma Cell Neurosphere Assay
Glioma cells were plated in nonadherent 6-well plates
(NUNC) at  3000 cells/cm
2 in neurosphere medium
(#05751 Neurocult NA-S proliferation human kit;
StemCell Technologies), supplemented with 20 ng/mL
EGF (Invitrogen), 20 ng/mL bFGF (Invitrogen), and
2 mg/mL heparin (Sigma). Growth factors were resup-
plemented every second day. Images were taken after
8 days, and spheres ≥50 mm in diameter were counted.
For analyses of serial sphere formation, spheres were
split with TrypLE Express (Invitrogen) when they
reached .100 mm in size, after which cells were resus-
pended and reseeded.
Limiting Dilution Assay
Limiting dilution assay was performed as described else-
where.
3,74 Cells were split and seeded in 96-well plates
with dilutions ranging from 1000 cells/well to 1 cell/
well in 200 mL NeuroCult media (StemCell
Technologies) supplemented as described above.
Supplements were added to cultures every second day.
After 7 days, the wells without spheres were counted
and plotted against the number of cells added per well.
The number of cells needed to form one sphere, which
represented the proportion of stem cells in the entire
culture population, was determined from the point at
which the line crossed at the 0.37 level.
74
Test of in vivo Tumorigenic Potential
In vivo tumorigenic potential of the primary tumor
material was analyzed as described in Supplemental
Material. Time to the development of visible tumor
was registered, as was time when tumor size reached
100 mm
3, 500 mm
3, and 1 cm
3.
Forxenograft assays of selected type A and type B cul-
tures, 500 000 cells were injected subcutaneously into
the low ﬂank of SCID mice. Three mice were used for
each cell culture. Tumor size was measured and moni-
tored daily until reaching a volume of  500 mm
3.
Then, animals were killed, and tumors were collected
(further details in Supplemental Material).
Detection of SOX2 by Immunoblotting
SOX2 protein levels were determined by sodium dodecyl
sulfate polyacrylamide gel electrophoresis and immuno-
blotting of cell lysates. Immunoblotting signals were
quantiﬁed using the AIDA software, version 3.10.039
(Raytest). See Supplemental Material for further details.
Analyses of Neurosphere Formation, Growth Rate, and
Gene Expression After siRNA-Mediated
Downregulation of SOX2
siRNA-mediated downregulation of SOX2 was done in
accordance with standard procedures (see
Supplemental Material).
Drug Treatment with Imatinib and NVP-AEW541 of
Cells Pretreated or not with SOX2 siRNA
Procedures for preparation of drug stock solutions,
siRNA-mediated downregulation, and immunoblotting
ofSOX2aredescribedindetailinSupplementalMaterial.
For analyses of effects on drug sensitivity, cells were
seeded at a density of 5000 cells per well in 96-well
plates, and were transfected with either SOX2 siRNA
or control siRNA on the next day. After 24 h, the cells
were retransfected and treated with 1 mM of imatinib
or 1 mM NVP-AEW541 for 72 h.
Supplementary Material
Supplementary material is available online at Neuro-
Oncology (http://neuro-oncology.oxfordjournals.org/)
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